Auxly Cannabis Group Inc.

TSX:XLY Stock Report

Market Cap: CA$35.3m

Auxly Cannabis Group Past Earnings Performance

Past criteria checks 0/6

Auxly Cannabis Group has been growing earnings at an average annual rate of 2.9%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 44.1% per year.

Key information

2.9%

Earnings growth rate

15.1%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate44.1%
Return on equity-87.2%
Net Margin-44.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

A Piece Of The Puzzle Missing From Auxly Cannabis Group Inc.'s (TSE:XLY) 33% Share Price Climb

Mar 21
A Piece Of The Puzzle Missing From Auxly Cannabis Group Inc.'s (TSE:XLY) 33% Share Price Climb

Auxly Cannabis Group Inc. (TSE:XLY) Stock Rockets 33% But Many Are Still Ignoring The Company

Feb 03
Auxly Cannabis Group Inc. (TSE:XLY) Stock Rockets 33% But Many Are Still Ignoring The Company

Take Care Before Jumping Onto Auxly Cannabis Group Inc. (TSE:XLY) Even Though It's 38% Cheaper

Dec 19
Take Care Before Jumping Onto Auxly Cannabis Group Inc. (TSE:XLY) Even Though It's 38% Cheaper

Does Auxly Cannabis Group (TSE:XLY) Have A Healthy Balance Sheet?

Oct 17
Does Auxly Cannabis Group (TSE:XLY) Have A Healthy Balance Sheet?

Is Auxly Cannabis Group (TSE:XLY) Using Debt In A Risky Way?

Jul 14
Is Auxly Cannabis Group (TSE:XLY) Using Debt In A Risky Way?

Auxly Cannabis Group Inc. (TSE:XLY) Could Be Riskier Than It Looks

Apr 17
Auxly Cannabis Group Inc. (TSE:XLY) Could Be Riskier Than It Looks

The Consensus EPS Estimates For Auxly Cannabis Group Inc. (TSE:XLY) Just Fell Dramatically

Aug 11
The Consensus EPS Estimates For Auxly Cannabis Group Inc. (TSE:XLY) Just Fell Dramatically

Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?

Jul 21
Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Auxly Cannabis Group Inc. (TSE:XLY) Revenue Forecasts By 8.2%

Aug 18
Growth Investors: Industry Analysts Just Upgraded Their Auxly Cannabis Group Inc. (TSE:XLY) Revenue Forecasts By 8.2%

Auxly Cannabis Group Inc. (TSE:XLY) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 29
Auxly Cannabis Group Inc. (TSE:XLY) Just Reported And Analysts Have Been Cutting Their Estimates

Breakeven On The Horizon For Auxly Cannabis Group Inc. (CVE:XLY)

Mar 24
Breakeven On The Horizon For Auxly Cannabis Group Inc. (CVE:XLY)

A Look At Auxly Cannabis Group's (CVE:XLY) Share Price Returns

Jan 28
A Look At Auxly Cannabis Group's (CVE:XLY) Share Price Returns

Revenue & Expenses Breakdown
Beta

How Auxly Cannabis Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:XLY Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23101-45400
30 Sep 2399-7400
30 Jun 2390-99420
31 Mar 2396-101480
31 Dec 2294-130510
30 Sep 2299-133540
30 Jun 22104-86530
31 Mar 2297-75490
31 Dec 2184-46460
30 Sep 2173-53420
30 Jun 2161-57420
31 Mar 2146-81420
31 Dec 2047-84470
30 Sep 2032-116490
30 Jun 2021-115540
31 Mar 2017-102530
31 Dec 198-103500
30 Sep 195-80530
30 Jun 194-72520
31 Mar 191-70520
31 Dec 181-67480
30 Sep 182-41440
30 Jun 182-38330
31 Mar 183-27240
31 Dec 172-18180
30 Sep 170-980
30 Jun 170-340
31 Mar 170-220
31 Dec 160010
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150000
30 Sep 150000
30 Jun 150000
31 Mar 150000
31 Dec 140000
30 Sep 140000
30 Jun 140000
31 Mar 140000
31 Dec 130000
30 Sep 130000
30 Jun 130000
31 Mar 130000

Quality Earnings: XLY is currently unprofitable.

Growing Profit Margin: XLY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XLY is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare XLY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XLY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).


Return on Equity

High ROE: XLY has a negative Return on Equity (-87.2%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.